Fifty patients scheduled for elective cholecystectomy were randomised to receive either indomethacin suppositories 200 mg p.r. at the end of anaesthesia, followed by 100 mg bd for three days, or placebo supppositories according to the same regimen. All patients were given intravenous pethidine via patient-controlled analgesia (peA) postoperatively. The mean dose of pethidine required by the patients in the indomethacin group was significantly less than that used by the placebo group, the cumulative dose after three days being 530.7 mg (SD 664.0) and 1151.0 mg (682.0) for the indomethacin and placebo groups respectively. At the same time the patients in the indomethacin group had lower pain scores both at rest and with movement, though this was only statistically significant on the first day on movement. There was no statistical difference between the groups with respect to the incidence of nausea, indigestion, proctitis, volume of drainage from the wound drain, or width of bruising around the wounds. Serum creatinine levels were compared pre-and postoperatively where possible and showed no change in either group.
Non-steroidal anti-inflammatory drugs (NSAIDs) are finding an increasing place in the management of postoperative pain. They have been successfully used as adjunct analgesic techniques following a wide range of surgery, including dental extraction, tonsillectomy, thoracic, gynaecological and orthopaedic surgery, their success being measured in terms of decreased pain scores and opioid requirements. 18 However, their role in abdominal surgery remains controversial. Reasbeck and Reasbeck 9 and Thind 10 found indomethacin to be of benefit in reducing pain scores and requirements for intramuscular morphine but noted problems with increased bleeding; other authors have found no significant benefit from NSAIDs. Furthermore, many studies have used parenteral NSAIDs not available commercially in Australia.
In the absence of parenteral preparations, suppositories have been the optimal mode of administration of NSAIDs following abdominal surgery, as gastric function in the immediate postoperative period will be obviously impaired. Owen et al. 8 used a patientcontrolled analgesic (PCA) device to demonstrate the opioid-sparing effects of ibuprofin suppositories given preoparatively and following lower-abdominal gynaecological surgery. However, the only commer-cially available suppositories in Australia at present are indomethacin, ketoprofen and naproxen.
This study was undertaken to examine the efficacy of indomethacin suppositories in reducing opioid requirements, as measured by PCA demands following open cholecystectomy.
METHODS
After obtaining institutional Ethics Committee approval and informed consent, fifty patients, ASA 1-3, scheduled for elective cholecystectomy, were enrolled in the trial. Patients were excluded if they had a history of peptic ulceration, bleeding disorder, renal impairment or haemorrhoids. All patients received a standard anaesthetic consisting of premedication with oral temazepam and metaclopramide, an intravenous induction followed by maintenance of anaesthesia with nitrous oxide and oxygen supplemented with enflurane; muscle relaxation was provided by vecuronium and intraoperative analgesia provided by pethidine as required. The patients were randomised into two groups by the sequential selection of previously randomised envelopes containing the patient grouping. The indomethacin group received two 100 mg indomethacin suppositories before reversal of anaesthesia, followed by 100 mg bd for three days. The placebo group received identical placebo suppositories according to the same regimen. Patients, nursing and medical staff were blinded as to which group the patients had been allocated.
All patients were given IV pethidine by PCA postoperatively, with a bolus dose of 10 mg, a fiveminute lock-out period and no four-hour dose limit. While on the PCA all patients were monitored by the Acute Pain Service. Postoperatively, the patients were assessed by one of the authors (JG) twice daily. Pain scores, as measured on a 100 mm linear analgesic scale, with one end marked "no pain at all" and the other end marked "the worst pain imaginable", were recorded at each postoperative visit, along with the dose of pethidine used. The pain scores were measured both at rest, on coughing and on moving from a lying to sitting position, pain on movement being taken as the greater value of the latter two. The patients were also asked if they had had any symptoms of nausea or proctitis since the last visit. The amount of fluid loss from the wound into drainage bottles over the first 24 hours was measured. The extent of wound bruising after three days was estimated by measuring the width of bruising around the wound with a ruler. In those patients who had had a preoperative serum creatinine measured, a second serum creatinine was measured after ceasing the suppositories and the two values were compared.
The data were analysed using t-tests and Chi-square tests, with a significance level of 5OJo.
RESULTS
The groups were evenly matched for age, weight and sex ratio (Table 1) . The difference between the mean ages of the two groups, 56.5 and 49.0 years, for the indomethacin and placebo groups respectively, was not statistically significant (P = 0.1). One patient in each group was lost due to failure to follow protocol. The mean dose of pethidine required by the patients in the indomethacin group was significantly less than that used by the placebo group at all times during the postoperative period (Table 2, Figure 1 ). At the same time the patients in the indomethacin group had lower pain scores both at rest and with movement though this was only statistically significant for pain on movement on day 1 am and pm and the morning of day 2 (Table 3, Figure 2 ). Age, mean, (SD) Weight kg (SD) Male/Female Table 5 shows no difference between the groups with respect to incidence of nausea or indigestion. There was a trend to slightly more indigestion occurring in the indomethacin group, but this did not reach statistical groups respectively (Table 4 ). These differences were not statistically significant. There were 19 patients in each group for which a preand postoperative serum creatinine level were available. In these patients, serum creatinine levels postoperatively compared with preoperative admission levels showed no significant change between the groups, being a fall of 1.5 Jlmolll (14.5) for the indomethacin group and a rise of 0.3 Jlmolll (17.4) for the placebo group (Table 4 ). The maximum rise in creatinine in these patients for each group was 28 J.tmolll for the indomethacin group and 26 J.tmolll for the placebo group.
DISCUSSION
This study confirms that indomethacin is a safe and effective supplement to PCA opiate analgesia following open cholecystectomy surgery. This is in accordance with the findings of Reasbeck and Reasbeck 9 and Thind 10 who looked at indomethacin following abdominal surgery. However, there are a number of important differences between these papers and this study.
While finding indomethacin to be effective in reducing opioid requirements, Reasbeck and Reasbeck,. and Thind,lo did not use PCA to more accurately determine patient postoperative analgesic requirements. PCA has become a widely used tool to determine the analgesic efficacy of various regimens while minimising bias caused by a system of pm analgesia administration, or fixed-dose IV infusion. Both these studies used doses of 100 mg tds, where We were able to achieve marked reduction in opioid requirements with a dose of 100 mg bd. This lower-dose regimen is likely to lead to greater patient and nursing staff acceptance, with a reduced morbidity. We did, however, administer a loading dose of 200 mg at the end of surgery, which few other trials have done. Pavy et al. 2 used a loading dose of 200 mg at the end of surgery for thoracotomy patients and achieved marked reduction in opioid requirements and pain scores at all points following surgery.
In their review of the use of NSAIDs for severe postoperative pain, Dahl and Kehlet 12 looked at a number of clinical studies comparing the effects of NSAIDs and placebo on postoperative pain and opioid requirements following major surgery. They found that in 11 of the 13 studies, pain intensity and/or opioid requirements were reduced by NSAIDs compared with placebo. They noted that the opioid-sparing effect was reported to vary between 20070 and 35%.
Kenny et aI., 12 while using PCA morphine to measure postoperative analgesia requirements, looked at the effect of ketorolac, either IV, IMI or IM infusion, in supplementing postoperative analgesia, and achieved a 42% reduction in opioid requirements. Similarly, Hodsman et al. 13 achieved a one-third reduction in PCA morphine requirements following abdominal surgery by using IM diclofenac. While successfully reducing their opioid requirements by more than onethird we have achieved opioid reductions of one-half with indomethacin, which is available in Australia in suppository form whereas ketorolac is only approved as IM injection and diclofenac as an oral preparation.
As would be expected, at all time points the pain scores on movement were greater than those at rest, and these differences steadily declined in the placebo group during the first three postoperative days.
NSAIDs have the potential to cause side-effects such as peptic ulceration, impairment of platelet function, impaired renal function and local irritation. We attempted to assess the incidence and severity of these side-effects in our patients and found no significant differences between the indomethacin and placebo groups. We also assessed the effect of the course of indomethacin on renal function by measuring changes in serum creatinine and found no increase. However, patients with a history of renal impairment or high preoperative creatinine were excluded from entry into the study.
Tawainen et al. 7 looked at the effect of indomethacin on postoperative bleeding and found a statistically significant increase in IVY bleeding times in the indomethacin group, but this was not a problem clinically. Similarly, Kristensen et al. 5 found no clinically or statistically significant difference in bleeding between an indomethacin and placebo treated group following total hip replacement. Owen et al. 8 also looked at intraoperative blood loss and postoperative wound bruising in patients who had ibuprufen prior to and following lower-abdominal gynaecological surgery. They found no difference between the two groups. Engel et al. I did find a significant increase in perioperative blood loss in their indomethacin treated group; however, in this study the indomethacin was commenced preoperatively as an IV bolus. The authors noted that a preoperative bolus offered little in the way of analgesia, yet may contribute to increased blood loss perioperatively. In our study blood loss as determined by wound drainage over the first 24 hours and area of wound bruising showed no difference between the indomethacin and placebo groups.
In conclusion rectal indomethacin 200 mg at the end of surgery and 100 mg bd given by suppository postoperatively for three days reduced PCA pethidine requirements by 50% with improved pain relief on movement and no increase in side-effects.
